Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070360 | 0.91 | LMNA (0.35) | GCKMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL278282 | 0.82 | GCK (0.39) | GCKMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL27193333 | 0.78 | LMNA (0.37) | MEN1KMT2ALMNAALDH1A1RAB9A | |
| SCHEMBL5502675 | 0.77 | LMNA (0.36) | MEN1KMT2ALMNAL3MBTL1ALDH1A1 | |
| SCHEMBL561821 | 0.76 | RAB9A (0.37) | MEN1KMT2ALMNAL3MBTL1ALDH1A1 | |
| SCHEMBL28384909 | 0.76 | MEN1 (0.41) | MEN1KMT2ALMNAALDH1A1RAB9A | |
| SCHEMBL30392206 | 0.76 | MEN1 (0.41) | MEN1KMT2ALMNAALDH1A1RAB9A | |
| SCHEMBL1679370 | 0.75 | EHMT2 (0.35) | GCKMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL8328957 | 0.75 | ALDH1A1 (0.39) | MEN1KMT2ALMNAALDH1A1RAB9A | |
| SCHEMBL278283 | 0.74 | TSHR (0.36) | MEN1KMT2ALMNARAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368574-A1 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-11-07 | — | — | US | disclosed |
| WO-2024123993-A1 | SELECTIVE APOPTOSIS-INDUCING METHODS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11839647-B2 | Methods for inducing partial apoptosis using caspase polypeptides | BELLICUM PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230270831-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2023-08-31 | — | — | US | disclosed |
| EP-4219544-A1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum (NL) | 2023-08-02 | — | — | EP | disclosed |
| EP-4201955-A1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum (NL) | 2023-06-28 | — | — | EP | disclosed |
| US-20230065562-A1 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-03-02 | — | — | US | disclosed |
| EP-3268014-B1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | ACADEMISCH ZIEKENHUIS LEIDEN H O D N LEIDS UNIV MEDISCH CENTRUM (NL) | 2022-09-21 | — | — | EP | disclosed |
| US-20220152100-A1 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-05-19 | — | — | US | disclosed |
| US-20220125837-A1 | METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-04-28 | — | — | US | disclosed |
| US-20150366954-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2015-12-24 | — | — | US | disclosed |
| US-20150328292-A1 | CASPASE POLYPEPTIDES HAVING MODIFIED ACTIVITY AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-11-19 | — | — | US | disclosed |
| WO-2015134877-A1 | CASPASE POLYPEPTIDES HAVING MODIFIED ACTIVITY AND USES THEREOF | BELLICUM PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-9089520-B2 | Methods for inducing selective apoptosis | BAYLOR COLLEGE OF MEDICINE (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2014197638-A2 | METHODS FOR INDUCING PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES | BELLICUM PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014164348-A2 | MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF | BELLICUM PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140255360-A1 | MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2014-09-11 | — | — | US | disclosed |
| US-20130323834-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BELLICUM PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2011146862-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BELLICUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110286980-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2011-11-24 | — | — | US | disclosed |